Grace Therapeutics (GRCE) Gains from Investment Securities (2019 - 2025)

Grace Therapeutics has reported Gains from Investment Securities for 7 years, with the latest figure at $40000.0 in Q4 2025.

• Quarterly Gains from Investment Securities fell 96.6% year-over-year to $40000.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was -$900000.0 (up 72.04% YoY) and the FY2026 annual result came in at -$900000.0, up 72.03% from the prior year.
• Gains from Investment Securities grew to $40000.0 in Q4 2025 per GRCE's latest filing, from -$1.4 million in the prior quarter.
• Over five years, Gains from Investment Securities peaked at $4.9 million in Q1 2022 and troughed at -$3.4 million in Q3 2021.
• A 5-year average of -$230125.0 and a median of -$243500.0 in 2023 frame the typical range for Gains from Investment Securities.
• The sharpest annual moves came in 2022 and 2025: Gains from Investment Securities surged 1069.05% in 2022, then tumbled 294.2% in 2025.
• Over 5 years, Gains from Investment Securities stood at -$828000.0 in 2021, then soared by 98.79% to -$10000.0 in 2022, then tumbled by 1150.0% to -$125000.0 in 2023, then soared by 1042.4% to $1.2 million in 2024, then slumped by 96.6% to $40000.0 in 2025.
• According to Business Quant data, Gains from Investment Securities over the past three periods registered $40000.0, -$1.4 million, and $487000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.